{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-174497","form_type":"8-K","ticker":"RCEL","cik":"0001762303","company_name":"AVITA Medical, Inc.","filed_at":"2023-06-26T23:59:59+00:00","discovered_at":"2026-05-14T18:03:40.443221+00:00","generated_at":"2026-06-13T17:11:38.470511+00:00","sec_items":["7.01","9.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"AVITA Medical reveals ~391K annual eligible procedures after expanded RECELL FDA approval","bullets":["Expanded FDA indication for full-thickness skin defects opens ~391,000 annual eligible procedures.","Traumatic wound market: ~127,000 procedures including degloving, crush, and avulsion.","Surgical wounds (including cancer excision) total ~264,000 eligible procedures.","Chronic wounds (DFU, VLU, pressure ulcers) account for ~128,000 annual procedures."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-174497","json":"https://secwatch.observer/filing/0001193125-23-174497.json","markdown":"https://secwatch.observer/filing/0001193125-23-174497.md","text":"https://secwatch.observer/filing/0001193125-23-174497.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/0001193125-23-174497-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1762303/000119312523174497/d521007d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T17:11:38.470511+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}